Advertisement

Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnerships 600x60px
Organisation › Details

Genkyotex (Group)

Genkyotex is a leading biopharmaceutical company in NOX therapies. Listed on the Euronext Paris and Euronext Brussels markets, Genkyotex is established in France and, via its GenKyoTex Suisse SA subsidiary, in Switzerland. A leader in NOX therapies, its unique therapeutic approach is based on a selective inhibition of NOX enzymes that amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. Genkyotex’s platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes. Genkyotex is developing a pipeline of first-in-class product candidates targeting one or multiple NOX enzymes. The lead product candidate, GKT831, a NOX1 and NOX4 inhibitor is expected to enter a phase II clinical trial in primary biliary cholangitis (PBC, an orphan fibrotic disease) during the first half of 2017. This product candidate may also be active in other fibrotic indications. Its second product candidate, GKT771, is a NOX1 inhibitor targeting multiple pathways in angiogenesis, pain processing, and inflammation, and should enter a phase I clinical study during the second half of 2017. Genkyotex also has a versatile platform, Vaxiclase, that is particularly well-suited to the development of various immunotherapies. A partnership covering the use of Vaxiclase as an antigen per se (GTL003) has been established with Serum Institute of India Ltd (Serum Institute), the world’s largest producer of vaccine doses. This agreement covers territories outside the United States and Europe, and could generate up to $57 million in revenues for Genkyotex, before royalties on sales. It will enable Serum Institute to develop acellular multivalent combination vaccines against a variety of infectious diseases, including whooping cough. The last preclinical milestone foreseen in the agreement was reached in November 2016, opening the path to formal preclinical testing prior to potential clinical development and subsequent commercialization. Following the realization of the aforementioned contribution transaction, the Company’s main shareholders are Eclosion, EdRIP, Vesalius, Neomed, Biomedinvest and VI Partners. *

 

Period Start 2006-01-01 established
Products Industry NOX inhibitor
  Industry 2 therapeutic vaccine
Persons Person Papatheodorou, Elias (Genkyotex 201707 before Covagen + Medigene + Novosom + A.T.I. + Coca-Cola + Philip Morris)
  Person 2 Timmerman, Benedikt (Genticel 201304 CEO + Founder)
     
Region Region Plan-les-Ouates GE
  Country Switzerland
  Street 16 Chemin des Aulx
  City 1228 Plan-les-Ouates GE
  Tel +44-22-880-1025
    Address record changed: 2018-07-24
     
Basic data Employees n. a.
  Currency EUR
  Cash 18,100,000 (2017-06-30)
     
    * Document for �About Section�: Genticel S.A.. (2/28/17). "Press Release: Genticel becomes “Genkyotex”. Genticel’s General Meeting Approves the Strategic Combination with GenKyoTex SA [Not for Australia, Canada, Japan, New Zealand, South Africa or the United States]". Toulouse & Geneva
     
   
Record changed: 2018-09-12

Advertisement

Picture EBD Group Bio-Europe 2018 Copenhagen Denmark November 600x60px

More documents for Genkyotex (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px




» top